Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial

详细信息    查看全文

• 作者：Prof Russell E Ware ; MD PhD^a ; ^{russell.ware@cchmc.org" class="auth_mail" title="E-mail the corresponding author} ; Prof Barry R Davis ; MD PhD^b ; William H Schultz ; MHS PA^a ; R Clark Brown ; MD PhD^c ; Banu Aygun ; MD^d ; Prof Sharada Sarnaik ; MD^e ; Prof Isaac Odame ; MBChB^f ; Beng Fuh ; MD^g ; Alex George ; MD PhD^h ; William Owen ; MDⁱ ; Prof Lori Luchtman-Jones ; MD^j ; Prof Zora R Rogers ; MD^k ; Prof Lee Hilliard ; MD^l ; Cynthia Gauger ; MD^m ; Connie Piccone ; MDⁿ ; Margaret T Lee ; MD^o ; Janet L Kwiatkowski ; MD MSCE^p ; Sherron Jackson ; MD^q ; Prof Scott T Miller ; MD^r ; Carla Roberts ; MD^s ; Matthew M Heeney ; MD^t ; Theodosia A Kalfa ; MD PhD^a ; Stephen Nelson ; MD^u ; Hamayun Imran ; MD^v ; Kerri Nottage ; MD MPH^w ; Prof Ofelia Alvarez ; MD^x ; Melissa Rhodes ; MD^y ; Prof Alexis A Thompson ; MD MPH^z ; Jennifer A Rothman ; MD^aa ; Kathleen J Helton ; MD^w ; Donna Roberts ; MD^q ; Jamie Coleman ; MD^w ; Prof Melanie J Bonner ; PhD^aa ; Prof Abdullah Kutlar ; MD^ab ; Niren Patel ; MD^ab ; John Wood ; MD PhD^ac ; Linda Piller ; MD^b ; Peng Wei ; PhD^b ; Judy Luden ; CCRC^q ; Nicole A Mortier ; MHS PA-C^a ; Susan E Stuber ; MA^a ; Prof Naomi L C Luban ; MD^j ; Prof Alan R Cohen ; MD^p ; Sara Pressel ; MS^b ; Prof Robert J Adams ; MD MS^q
• 刊名：The Lancet
• 出版年：2016
• 出版时间：13-19 February 2016
• 年：2016
• 卷：387
• 期：10019
• 页码：661-670
• 全文大小：552 K

文摘

For children with sickle cell anaemia and high transcranial doppler (TCD) flow velocities, regular blood transfusions can effectively prevent primary stroke, but must be continued indefinitely. The efficacy of hydroxycarbamide (hydroxyurea) in this setting is unknown; we performed the TWiTCH trial to compare hydroxyurea with standard transfusions.

Methods

TWiTCH was a multicentre, phase 3, randomised, open-label, non-inferiority trial done at 26 paediatric hospitals and health centres in the USA and Canada. We enrolled children with sickle cell anaemia who were aged 4–16 years and had abnormal TCD flow velocities (≥200 cm/s) but no severe vasculopathy. After screening, eligible participants were randomly assigned 1:1 to continue standard transfusions (standard group) or hydroxycarbamide (alternative group). Randomisation was done at a central site, stratified by site with a block size of four, and an adaptive randomisation scheme was used to balance the covariates of baseline age and TCD velocity. The study was open-label, but TCD examinations were read centrally by observers masked to treatment assignment and previous TCD results. Participants assigned to standard treatment continued to receive monthly transfusions to maintain 30% sickle haemoglobin or lower, while those assigned to the alternative treatment started oral hydroxycarbamide at 20 mg/kg per day, which was escalated to each participant's maximum tolerated dose. The treatment period lasted 24 months from randomisation. The primary study endpoint was the 24 month TCD velocity calculated from a general linear mixed model, with the non-inferiority margin set at 15 cm/s. The primary analysis was done in the intention-to-treat population and safety was assessed in all patients who received at least one dose of assigned treatment. This study is registered with ClinicalTrials.gov, number NCT01425307.

Findings

Between Sept 20, 2011, and April 17, 2013, 159 patients consented and enrolled in TWiTCH. 121 participants passed screening and were then randomly assigned to treatment (61 to transfusions and 60 to hydroxycarbamide). At the first scheduled interim analysis, non-inferiority was shown and the sponsor terminated the study. Final model-based TCD velocities were 143 cm/s (95% CI 140–146) in children who received standard transfusions and 138 cm/s (135–142) in those who received hydroxycarbamide, with a difference of 4·54 (0·10–8·98). Non-inferiority (p=8·82 × 10⁻¹⁶) and post-hoc superiority (p=0·023) were met. Of 29 new neurological events adjudicated centrally by masked reviewers, no strokes were identified, but three transient ischaemic attacks occurred in each group. Magnetic resonance brain imaging and angiography (MRI and MRA) at exit showed no new cerebral infarcts in either treatment group, but worsened vasculopathy in one participant who received standard transfusions. 23 severe adverse events in nine (15%) patients were reported for hydroxycarbamide and ten serious adverse events in six (10%) patients were reported for standard transfusions. The most common serious adverse event in both groups was vaso-occlusive pain (11 events in five [8%] patients with hydroxycarbamide and three events in one [2%] patient for transfusions).

Interpretation

For high-risk children with sickle cell anaemia and abnormal TCD velocities who have received at least 1 year of transfusions, and have no MRA-defined severe vasculopathy, hydroxycarbamide treatment can substitute for chronic transfusions to maintain TCD velocities and help to prevent primary stroke.

Funding

National Heart, Lung, and Blood Institute, National Institutes of Health.